Assessing Nanoparticle Detectability via 1 H Chemical Shift Imaging
Chemical & Biomedical Imaging · 2026-07-22
DOI: 10.1021/cbmi.6c00107 ↗At a glance
Journal article in Chemical & Biomedical Imaging, published online on 2026-07-22. Written by Alice Santangelo and 3 co-authors. 54 references. The full text is freely available (open access, CC BY 4.0). Funded by: Ministero dell'Universit? e della Ricerca.
Abstract (original language)
: Chemical shift imaging (CSI) based on proton magnetic resonance enables label-free detection of nanocarriers, providing quantitative and spatially resolved information without the need for specific labeling tracers. Here, we evaluated the feasibility of 1 H CSI to detect, quantify, and track nanosystems across in vitro, in cellulo, and in vivo settings. Five representative formulations � polymeric micelles (F127-MICs), PEGylated liposomes (Lipo-PEG), fluorinated nanoemulsions (PFCE-NEs), PLGA nanoparticles (PLGA-NPs), and paramagnetic liposomes (Lipo-Yb) � were characterized in terms of physicochemical properties, proton content, and spectral signatures. High-resolution 1 H NMR quantified nanoparticle uptake in RAW 264.7 macrophages, revealing formulation-dependent internalization efficiencies (0.08 − 1.55%). Despite low uptake fractions, intracellular proton pools ( ∼ 1 − 6 μ mol) enabled reliable detection. Washout experiments highlighted pronounced differences in intracellular persistence: PFCE-NEs and F127-MICs retained most of their signal ( ≤ 22% reduction after 4 h), whereas Lipo-Yb and PLGA-NPs exhibited >70% signal loss. Combined 1 H/ 19 F analysis of PFCE-NEs showed that protonated components undergo biodegradation, while the fluorinated core persists. 1 H CSI experiments further demonstrated that detectability depends on proton density, spectral separation from endogenous signals, and intracellular stability. Finally, in vivo proof-of-concept studies at 7 T detected intratumoral accumulation of PEGylated liposomes, supporting the translational potential of label-free proton imaging. Overall, this work establishes 1 H CSI as a quantitative strategy for nanoparticle evaluation and identifies formulation parameters governing intracellular detectability and clinical feasibility in nanomedicine
Funding
- Ministero dell'Universit? e della Ricerca
Cite
APA
Santangelo, A., Marzano, F., Garello, F., & Terreno, E. (2026). Assessing Nanoparticle Detectability via 1 H Chemical Shift Imaging. Chemical & Biomedical Imaging. https://doi.org/10.1021/cbmi.6c00107
Vancouver
Santangelo A, Marzano F, Garello F, Terreno E. Assessing Nanoparticle Detectability via 1 H Chemical Shift Imaging. Chemical & Biomedical Imaging. 2026. doi:10.1021/cbmi.6c00107
BibTeX
@article{Santangelo2026,
author = {Santangelo, Alice and Marzano, Federico and Garello, Francesca and Terreno, Enzo},
title = {Assessing Nanoparticle Detectability via 1 H Chemical Shift Imaging},
journal = {Chemical & Biomedical Imaging},
year = {2026},
doi = {10.1021/cbmi.6c00107}
}
EUVIMED